Bausch & Lomb (FRA:S2L) Cash And Cash Equivalents : €290 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Cash And Cash Equivalents?

Bausch & Lomb's quarterly cash and cash equivalents declined from Sep. 2023 (€332.64 Mil) to Dec. 2023 (€303.53 Mil) but then stayed the same from Dec. 2023 (€303.53 Mil) to Mar. 2024 (€289.80 Mil).

Bausch & Lomb's annual cash and cash equivalents increased from Dec. 2021 (€153.99 Mil) to Dec. 2022 (€334.18 Mil) but then declined from Dec. 2022 (€334.18 Mil) to Dec. 2023 (€303.53 Mil).

Bausch & Lomb Cash And Cash Equivalents Historical Data

The historical data trend for Bausch & Lomb's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Cash And Cash Equivalents Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

172.80

195.64

153.99

334.18

303.53

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial												323.16	354.43	332.64	303.53	289.80

Bausch & Lomb Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Bausch & Lomb (FRA:S2L) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Bausch & Lomb Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (FRA:S2L) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (FRA:S2L) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

BLCO:USA BLCO:Canada

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Bausch & Lomb (FRA:S2L) Headlines

No Headlines